Zusammenfassung
Das Glioblastom ist der häufigste maligne Hirntumor beim Erwachsenen. Er wächst meist supratentoriell. Die klinische Symptomatik reflektiert Tumorlokalisation und hohe Wachstumsgeschwindigkeit. Das kontrastmittelunterstütze MRT lässt häufig schon präoperativ die Diagnose stellen. Eine Histologiesicherung gegebenenfalls nur bioptisch ist aber obligat. Therapie der Wahl ist die möglichst vollständige Tumorresektion je nach Lebensalter und Molekulargenetik (MGMT-Status), gefolgt von Strahlen- bzw. Chemotherapie (mit Temozolomid). Tumorteilresektionen können die Ausgangsbedingungen für die adjuvante Therapie verbessern bzw. überhaupt erst schaffen. Die Prognose von Patienten mit einem Glioblastom ist trotz multimodaler Behandlung mit einer mittleren Lebenserwartung von weniger als 1–1,5 Jahren schlecht.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Bruna J, Miro J, Velasco R (2013) Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment. Expert Rev Clin Pharmacol 6: 333–344.
Chang SM, Parney IF, McDermott M et al. (2003) Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg 98: 1175–1181.
De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS (2012) Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 30: 2559–2565.
Eyupoglu IY, Buchfelder M, Savaskan NE (2013) Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat Rev Neurol 9: 141–151.
Gulati S, Jakola AS, Nerland US, Weber C, Solheim O (2011) The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg 76: 572–579.
Jo JT, Schiff D, Perry JR (2014) Thrombosis in brain tumors. Semin Thromb Hemost 40: 325–331.
Karsy M, Gelbman M, Shah P, Balumbu O, Moy F, Arslan E (2012) Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol 50: 301–321.
Malmstrom A, Gronberg BH, Marosi C et al. (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol13: 916–926.
McGirt MJ, Chaichana KL, Gathinji M et al. (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110: 156–162.
Morais N, Mascarenhas L, Soares-Fernandes JP, Silva A, Magalhaes Z, Costa JA: Primary spinal glioblastoma: A case report and review of the literature. Oncol Lett 5: 992–996.
Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445–1453.
Ostrom QT, Gittleman H Farah P et al. (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15 Suppl 2: ii1–56.
Posti JP, Bori M, Kauko T et al. (2015) Presenting symptoms of glioma in adults. Acta Neurol Scand 131: 88–93.
Roa W, Brasher PM, Bauman G et al. (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22: 1583–1588.
Robert Koch-Institut (RKI), Gesellschaft der epidemiologischen Krebsregister in Deutschland (GEKID) e. V. (2010) Krebs in Deutschland 2005/2006. Haufigkeiten und Trends. 7. Ausgabe. Berlin, 2010. Online verfügbar unter: http://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsB/KID2010.pdf?__blob=publicationFile. Zugegriffen: 25.10.2016.
Sadetzki S, Bruchim R, Oberman B et al. (2013) Description of selected characteristics of familial glioma patients – results from the Gliogene Consortium. Eur J Cancer 49: 1335–1345.
Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115: 3–8.
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7: 392–401.
Sturm D, Witt H, Hovestadt V et al. (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22: 425–437.
Thomas RP, Xu LW, Lober RM, Li G, Nagpal S (2013) The incidence and significance of multiple lesions in glioblastoma. J Neurooncol 2013;112:91–97.
Verhaak RG, Hoadley KA, Purdom E et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98–110.
Wick W, Platten M, Meisner C et al. (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol13: 707–715.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Krex, D., Schackert, G. (2018). Glioblastome. In: Simon, M. (eds) Gliomchirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48694-8_25
Download citation
DOI: https://doi.org/10.1007/978-3-662-48694-8_25
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-48693-1
Online ISBN: 978-3-662-48694-8
eBook Packages: Medicine (German Language)